Histotype
Myeloma
| Parameter | Information |
|---|---|
| Strain | C57BL/KaLwRijHsd |
| Implant Type | Cells |
| Implant Location | IV |
| Time to Staging | 7 days |
| Td | 2.8 days |
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.
Tumor Line
Mouse
Ref #
9062
Spotlight on 5TGM1-luc
Learn more about this cell line in our scientific spotlights:
Multiple myeloma is a malignancy of plasma B cells and is the second most common hematological malignancy in the United States. Malignant myeloma cells accumulate in the bone marrow and ultimately replace normal hematopoetic stem cells, which results in progressive leukocyte deficiencies. Chemotherapeutic agents and proteasome inhibitors are standard-of-care front line therapy that is often followed by autologous stem cell transplantation. Relapse is common with these treatment strategies,1 and research toward novel targeted therapies and immuno-therapies is being pursued aggressively.